Moonray Healthcare today announced the acquisition of Lexum, the market leading provider of ophthalmology in Czech Republic and Poland.
Moonray Healthcare today announced the acquisition of Lexum, the market leading provider of ophthalmology in Czech Republic and Poland.
The deal will see a phased transfer of ownership from current investors ARX Equity Partners and founder Professor Martin Filipec who will remain with the group.
Lexum operates 10 hospitals across Central Europe including the European Eye Centre, a new 2,500m2 flagship eye hospital in Prague. Moonray Healthcare intends to combine the group with Optegra®, its specialist eye hospital group which operates 11 eye hospitals across England and Germany. Together the group will annually perform more than 40,000 surgical procedures and be one of the world’s largest providers of ophthalmology.
Moonray Healthcare and Optegra CEO, Tim Clover, commented that Lexum provided Optegra with a high quality growth platform in an exciting region. "We see lots of similarities between the two groups in terms of quality, innovation and strategy which means that for patients, doctors and employees this marriage makes perfect sense. We hope to exchange the great ideas that we have seen in due diligence between the two companies and further improve patient care and business performance. This investment in Lexum is the latest stage of a significant expansion plan which will continue in further regions. “
Professor Martin Filipec who founded Lexum and continues as Chief Medical Officer commented: “Optegra and Lexum both deliver a broad range of premium care in ophthalmology from CLARIVU ™, cataract and vitreoretinal surgery, laser refractive surgery, corneal transplants, strabism and oculoplastics surgery. Both companies are professionally driven with prominent doctor engagement and strong external links to ophthalmic research and development.
“I believe that the combined company will be able to contribute to real innovation in eye care and also act as a partner to the medical device industry in the further development and adoption of the latest technology, which will bring real benefits to patients.”
Professor Filipec went on to thank ARX Equity Partners for its support in building Lexum across both Czech Republic and Poland.
Financial details of the transaction were not disclosed.
Select a suggestion below...